8Mes·

Small update

$UTHR (-3,22%) time is running out and I'm getting downright panicky. Not even a month left until $LQDA (-2,13%) the sale of the PAH drug starts (PH-ILD approval still pending). Liquidia CEO (former CEO of UTHR) aims to gain 80-90% of market share.

attachment
3
Partecipa alla conversazione